CDKN2A and cancer: Pathologists evaluate P53 and P16 IHC staining in cancers by reviewing the overall staining intensity and pattern across the lesion and classify tumors as normal (heterogeneous staining across the lesion), null or overexpression for P53 and normal or overexpression for P16 [33, 34].